Hugo Poirier
Aegera Therapeutics (Canada)(CA)
Publications by Year
Research Areas
Cancer therapeutics and mechanisms, Drug Transport and Resistance Mechanisms, DNA Repair Mechanisms, Antimicrobial Resistance in Staphylococcus, Heart Failure Treatment and Management
Most-Cited Works
- → MF498 [N-{[4-(5,9-Diethoxy-6-oxo-6,8-dihydro-7 H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-(2-methoxyphenyl)acetamide], a Selective E Prostanoid Receptor 4 Antagonist, Relieves Joint Inflammation and Pain in Rodent Models of Rheumatoid and Osteoarthritis(2008)98 cited
- → Linking Bisphosphonates to the Free Amino Groups in Fluoroquinolones: Preparation of Osteotropic Prodrugs for the Prevention of Osteomyelitis(2008)74 cited
- → Identification of RP-6685, an Orally Bioavailable Compound that Inhibits the DNA Polymerase Activity of Polθ(2022)62 cited
- → Bisphosphonated fluoroquinolone esters as osteotropic prodrugs for the prevention of osteomyelitis(2008)44 cited
- → Biarylimidazoles as inhibitors of microsomal prostaglandin E2 synthase-1(2010)32 cited
- → Novel non-nucleobase inhibitors of Staphylococcus aureus DNA polymerase IIIC(2005)19 cited
- → Allotopic antagonism of the non-peptide atrial natriuretic peptide (ANP) antagonist HS-142-1 on natriuretic peptide receptor NPR-A(2002)11 cited
- → A membrane vesicle-based assay to enable prediction of human biliary excretion(2013)9 cited
- → The Discovery of RP-2119: A Potent, Selective, and Orally Bioavailable Polθ ATPase Inhibitor(2025)7 cited